Fine J P
Department of Statistics and Department of Biostatistics & Medical Informatics, University of Wisconsin, Madison, WI 53706, USA.
Biostatistics. 2001 Mar;2(1):85-97. doi: 10.1093/biostatistics/2.1.85.
In a randomized trial of tamoxifen therapy for breast cancer, women can experience tumor recurrence or die from competing causes. One goal of analysis is to describe the effect of tamoxifen on the probabilities of recurrence or death from other causes. To this end, we propose a semi-parametric transformation model for the crude failure probabilities of a competing risk, conditional on covariates. The model is developed as an extension of the standard approach to survival data with independent right censoring. Estimation of the regression coefficients is achieved with a rank-based least squares criterion. Simulations show that the procedure works well with practical sample sizes. A separate estimating function is developed for the baseline parameter. Prediction of covariate-adjusted failure probabilities is considered. The methodology is motivated and illustrated with data from the tamoxifen trial.
在一项他莫昔芬治疗乳腺癌的随机试验中,女性可能会出现肿瘤复发或因其他原因死亡。分析的一个目标是描述他莫昔芬对复发概率或其他原因导致死亡概率的影响。为此,我们提出了一个半参数转换模型,用于在协变量条件下竞争风险的粗失败概率。该模型是作为具有独立右删失的生存数据标准方法的扩展而开发的。回归系数的估计通过基于秩的最小二乘准则来实现。模拟表明,该方法在实际样本量下效果良好。为基线参数开发了一个单独的估计函数。考虑了协变量调整失败概率的预测。该方法以他莫昔芬试验的数据为动机并进行了说明。